Rosen Law Firm Probes Telix Pharmaceuticals Over Potential Securities Fraud
The Rosen Law Firm, a renowned name in securities class actions, has recently launched an investigation into potential claims against Telix Pharmaceuticals Ltd. (NASDAQ: TLX). The firm, which has secured hundreds of millions for investors in previous cases, is exploring allegations that Telix may have misled investors with materially false business information.
On July 22, 2025, Telix received a subpoena from the U.S. Securities and Exchange Commission, seeking documents and information related to its disclosures about its prostate cancer therapeutic candidates. This news sent Telix's American Depositary Receipt (ADR) price tumbling by $1.70 per ADR, or 10.44%, to $14.58 per ADR the following day.
Founded by Laurence Rosen, the firm has a proven track record, securing over $438 million for investors in 2019 alone. In 2020, Rosen was recognized as a Titan of Plaintiffs' Bar by law360. Shareholders who purchased Telix securities may be entitled to compensation through a contingency fee arrangement. The Rosen Law Firm encourages investors to choose qualified counsel for securities class actions.
The Rosen Law Firm is investigating these claims on behalf of Telix shareholders. Investors can follow the firm for updates on its social media platforms, including LinkedIn, Twitter, and Facebook. If you have any questions or wish to discuss your legal options, you can contact the Rosen Law Firm directly.
Read also:
- Small Business Owners Sound Alarm on Tariff Challenges
- THW Marks 75 Years of Saving Lives at Home and Abroad
- Kazakhstan's National Bank Boosts Currency Sales to $1.4 Trillion in Q4
- Federal petition from CEI seeking federal intervention against state climate disclosure laws, alleging these laws negatively impact interstate commerce and surpass constitutional boundaries.
